Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Assessing Cosopt Switch Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00273442
Recruitment Status : Completed
First Posted : January 9, 2006
Last Update Posted : November 19, 2008
Information provided by:
Pharmaceutical Research Network

Brief Summary:
To assess the safety and efficacy of a cohort of patients switched to the dorzolamide/timolol maleate fixed combination because they are insufficiently controlled on latanoprost monotherapy.

Condition or disease Intervention/treatment Phase
Ocular Hypertension Open-Angle Glaucoma Exfoliation Syndrome Glaucoma, Pigmentary Drug: timolol maleate Drug: dorzolamide/timolol maleate fixed combination Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 60 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Study Start Date : November 2005
Actual Study Completion Date : April 2007

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • adults with clinical diagnosis of POAG, pigment-dispersion or exfoliation glaucoma or ocular hypertension
  • the IOP on latanoprost must be 31 mm Hg or less in both eyes, and 21 to 31 mm Hg inclusive in at least one eye at 08:00 AM
  • visual acuity should be 20/200 or better in each eye

Exclusion Criteria:

  • contraindications to study drugs
  • anticipated change in systemic hypotensive therapy during the trial
  • use of any corticosteroids by any route in the three months immediately prior to Visit 2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00273442

Layout table for location information
United States, Arkansas
Little Rock Eye Clinic
Little Rock, Arkansas, United States, 72205
United States, Georgia
Omni Eye Services
Atlanta, Georgia, United States, 30342
United States, Illinois
Midwest Eye Center
Bourbonnais, Illinois, United States, 60914
United States, Oklahoma
Mark J. Weiss, MD
Tulsa, Oklahoma, United States, 74104
United States, South Carolina
Glaucoma Consultants & Center for Eye Research
Mt. Pleasant, South Carolina, United States, 29464
Sponsors and Collaborators
Pharmaceutical Research Network
Layout table for investigator information
Study Director: William C. Stewart, MD Pharmaceutical Research Network, LLC
Principal Investigator: Mark J. Weiss, MD
Principal Investigator: Douglas G. Day, MD Omni Eye Services
Principal Investigator: Sriram Sonty, MD, FACS Midwest Eye Center
Principal Investigator: J. Charles Henry, MD Little Rock Eye Clinic
Principal Investigator: Elizabeth D. Sharpe, MD Glaucoma Consultants & Center for Eye Research
Layout table for additonal information Identifier: NCT00273442    
Other Study ID Numbers: PRN 05-007
First Posted: January 9, 2006    Key Record Dates
Last Update Posted: November 19, 2008
Last Verified: November 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Glaucoma, Open-Angle
Ocular Hypertension
Exfoliation Syndrome
Eye Diseases
Iris Diseases
Uveal Diseases
Maleic acid
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Anti-Arrhythmia Agents
Antihypertensive Agents
Enzyme Inhibitors
Carbonic Anhydrase Inhibitors